Literature DB >> 24530360

Ultrastructural aspects of melatonin cytotoxicity on Caco-2 cells in vitro.

Ana Paula C Batista1, Terezinha G da Silva2, Alvaro A C Teixeira3, Paloma L de Medeiros4, Valeria W Teixeira1, Luiz C Alves5, Fábio A B Dos Santos5, Eliete C Silva4.   

Abstract

Colon adenocarcinoma is a disease expanding worldwide. Cancer of colon and rectum are among the top ten most insidious types in Brazil. In vitro and in vivo studies have demonstrated the efficacy of the hormone melatonin to prevent and reduce tumor growth. However, there are only few studies addressing the action of melatonin on Caco-2 cells. Thus, the cytotoxic effect of melatonin on the ultrastructure of Caco-2 cells was investigated. The MTT colorimetric method was used to assess the cytotoxicity. A total of 2×10(6)cells/mL were seeded in microplates and incubated at 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78 and 0.0 (control) μg/mL of melatonin. For ultrastructural analysis concentrations with low, medium and high cytotoxicity plus the control were used for ultrastructural analysis. The concentrations 50, 1.56 and 0.78 μg/mL of melatonin showed low, medium and high cytotoxicity, respectively. Ultrastructurally, the control tumor cells were shown to be preserved. Caco-2 cells showed morphological changes at 50 μg/mL of melatonin, with numerous vacuoles, mitochondrial degeneration and reduced glycogen. However, Caco-2 cells also showed altered morphology in treatments at 1.56 and 0.78 μg/mL of melatonin with characteristics of cells in degeneration by the presence of numerous vacuoles, absence of microvilli, mitochondrial degeneration and nuclear fragmentation. Thus, one can infer that concentrations of 1.56 and 0.78 μg/mL of melatonin promote cytotoxicity in Caco-2 cells, which can probably be related to the generation of reactive oxygen species (ROS).
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Caco-2; Cytotoxicity; Melatonin; Ultrastructure

Mesh:

Substances:

Year:  2013        PMID: 24530360     DOI: 10.1016/j.micron.2013.12.003

Source DB:  PubMed          Journal:  Micron        ISSN: 0968-4328            Impact factor:   2.251


  8 in total

Review 1.  Role of melatonin in traumatic brain injury and spinal cord injury.

Authors:  Mehar Naseem; Suhel Parvez
Journal:  ScientificWorldJournal       Date:  2014-12-21

Review 2.  Melatonin for the prevention and treatment of cancer.

Authors:  Ya Li; Sha Li; Yue Zhou; Xiao Meng; Jiao-Jiao Zhang; Dong-Ping Xu; Hua-Bin Li
Journal:  Oncotarget       Date:  2017-06-13

Review 3.  Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin Antioncogenic Action.

Authors:  Hucong Wu; Jiaqi Liu; Yi Yin; Dong Zhang; Pengpeng Xia; Guoqiang Zhu
Journal:  Biomed Res Int       Date:  2019-09-17       Impact factor: 3.411

4.  Melatonin inhibits proliferation and viability and promotes apoptosis in colorectal cancer cells via upregulation of the microRNA-34a/449a cluster.

Authors:  Guangyu Ji; Wenjuan Zhou; Xian Li; Jingyi Du; Xinyue Li; Hongbo Hao
Journal:  Mol Med Rep       Date:  2021-01-05       Impact factor: 2.952

Review 5.  Oncostatic-Cytoprotective Effect of Melatonin and Other Bioactive Molecules: A Common Target in Mitochondrial Respiration.

Authors:  Nicola Pacini; Fabio Borziani
Journal:  Int J Mol Sci       Date:  2016-03-07       Impact factor: 5.923

Review 6.  The role of melatonin in colorectal cancer treatment: a comprehensive review.

Authors:  Mindaugas Kvietkauskas; Viktorija Zitkute; Bettina Leber; Kestutis Strupas; Philipp Stiegler; Peter Schemmer
Journal:  Ther Adv Med Oncol       Date:  2020-07-17       Impact factor: 8.168

7.  Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments.

Authors:  Aroha B Sánchez; Ana C Calpena; Mireia Mallandrich; Beatriz Clares
Journal:  Pharmaceutics       Date:  2019-11-29       Impact factor: 6.321

8.  Use of Melatonin Is Associated With Lower Risk of Colorectal Cancer in Older Adults.

Authors:  Naiqi Zhang; Jan Sundquist; Kristina Sundquist; Jianguang Ji
Journal:  Clin Transl Gastroenterol       Date:  2021-08-03       Impact factor: 4.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.